Effect of varenicline and bupropion SR on craving ... - CiteSeerX
Recommend Documents
The net health benefit (NHB) of nicotine replacement therapy. Cost-effectiveness of varenicline, bupropion and nicotine replace- ment therapy for smoking.
Apr 30, 2015 - Cannabis is the most commonly used illicit drug of abuse in New. Zealand (NZ); in 2008 15% of those aged 16-64 years of age reported.
Oct 12, 2005 - VNTR polymorphism moderated the effects of alcohol on craving and other ..... future studies also need to examine the long-term effects.
scores without similarly affecting withdrawal symptoms. ... ing as a non-specific vector connected to the ... drawal was assessed by the Scale for alcohol.
May 21, 2013 - effect of varenicline on individual nicotine Withdrawal symptoms: a Combined analysis of eight randomized,. Placebo-Controlled trials.
The nicotinic agonist varenicline is a new alternative replacement agonist. There are no reports of its use in schizophrenia. We present the case of a patient with.
Jolene Berg, Bruce Berwald, James Borders,. Robert Buynak ... George Raad, Eric Ross, Robert Schrieman,. Sherwyn .... Turnbull FM, Abraira C, Anderson RJ,.
Evaluating the effects of diagenesis on the isotopic compositions of Sr, ... vation represents the addition of Sr to the shell during diagenesis, we calculate that the.
Mar 9, 2015 - Patients who have a seizure while taking varenicline should stop the medicine and seek medical attention i
Because laser ablation is faster, less expensive, and less destructive than bulk sampling solution methods, it opens the ... E-mail: [email protected].
Effect of varenicline and bupropion SR on craving ... - CiteSeerX
Psychopharmacology (2008) 197:371–377 DOI 10.1007/s00213-007-1041-3
ORIGINAL INVESTIGATION
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt Robert West & Christine L. Baker & Joseph C. Cappelleri & Andrew G. Bushmakin
Received: 27 July 2007 / Accepted: 3 December 2007 / Published online: 15 December 2007 # Springer-Verlag 2007
Abstract Aims To examine the effect of varenicline, a selective alpha4-beta2 nicotinic acetylcholine receptor (nAChR) partial agonist, on craving and withdrawal symptoms in smokers making a quit attempt and the rewarding effects of smoking during a lapse after the target quit date (TQD). Materials and methods Pooled data were analysed from two identical double-blind, randomised trials comparing varenicline 1 mg BID, bupropion (sustained release) 150 mg BID and placebo using measures of craving and withdrawal in the first week after the TQD (in abstinent [n= 612] and non-abstinent participants [n=1,155]) and of the rewarding effects of the first cigarette smoked in nonabstinent participants. Results In abstinent and non-abstinent participants combined, varenicline reduced craving more than bupropion (p
